DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION
THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 29, 2023 AND SEPTEMBER 30, 2022
TABLE OF CONTENTS
Page
- Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
- Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes
- Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Ratio and Free Cash Flow to Net Earnings Conversion Ratio
- Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions (including the pending acquisition of Abcam plc) and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023. These forward-looking statements speak only as of the date of this document (October 23, 2023) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
DANAHER CORPORATION
Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment
% Change Three-Month Period Ended September 29, 2023 vs. Comparable 2022 Period
Segments
Total sales (decline) growth (GAAP)
Impact of:
Acquisitions/divestitures
Currency exchange rates
Core sales (decline) growth (non-GAAP)
Impact of COVID-19 related testing, vaccines and therapeutics
Base business core sales (decline) growth (non-GAAP)
Total sales (decline) growth (GAAP)
Impact of:
Acquisitions/divestitures
Currency exchange rates
Core sales (decline) growth (non-GAAP)
Impact of COVID-19 related testing, vaccines and therapeutics
Base business core sales growth (decline) (non-GAAP)
Environmental & | ||||||||
Total Company | Biotechnology | Life Sciences | Diagnostics | Applied | ||||
Solutions | ||||||||
(10.5)% | (19.0)% | (1.0)% | (16.0)% | 3.5 % | ||||
(0.5)% | (0.5)% | (1.0)% | - % | (0.5)% | ||||
(0.5)% | (1.5)% | (0.5)% | 0.5 % | (2.0)% | ||||
(11.5)% | (21.0)% | (2.5)% | (15.5)% | 1.0 % | ||||
8.5 % | +Mid-single | +Up slightly | +Low-twenties | - % | ||||
digit | ||||||||
(3.0)% | -Mid-teens | -Low-single | +Mid-single | 1.0 % | ||||
digit | digit | |||||||
- Change Nine-Month Period Ended September 29, 2023 vs. Comparable 2022 Period Segments
Environmental & | ||||||||
Total Company | Biotechnology | Life Sciences | Diagnostics | Applied | ||||
Solutions | ||||||||
(8.0)% | (17.0)% | 2.5 % | (13.0)% | 3.5 % | ||||
(0.5)% | - % | (1.0)% | - % | (0.5)% | ||||
1.0 % | 0.5 % | 1.0 % | 1.5 % | - % | ||||
(7.5)% | (16.5)% | 2.5 % | (11.5)% | 3.0 % | ||||
9.0 % | +High-single | +Low-single | +Low-twenties | - % | ||||
digit | digit | |||||||
1.5 % | -High-single | +Mid-single+High-single | 3.0 % | |||||
digit | digit | digit | ||||||
Note: We expect overall demand for the Company's COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand for the Company's products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the Company's products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore, beginning with the first quarter of 2023, we have revised the definition of "base business core sales growth" on a basis that not only excludes revenues related to COVID-19 testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of "base business core sales growth" provides more useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company's business that otherwise may be obscured by fluctuations in demand for COVID-19 related products.
1
DANAHER CORPORATION
Forecasted Core Sales (Decline) Growth, Base Business Core Sales (Decline) Growth and Adjusted Operating Profit Margin
The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit. On September 30, 2023, the Company completed the separation of its former Environmental & Applied Solutions business by distributing to Danaher stockholders on a pro rata basis all of the issued and outstanding common stock of Veralto Corporation ("Veralto"). The reporting of Veralto as a discontinued operation will be reflected in the Company's future filings, but in no way revises or restates any Consolidated Statements of Earnings for any period previously filed with the U.S. Securities and Exchange Commission.
% Change Three-Month | % Change Year Ending | ||
Period Ending December | |||
31, 2023 vs. Comparable | December 31, 2023 vs. | ||
2022 Period | Comparable 2022 Period | ||
Core sales decline from continuing operations reflecting Veralto as a discontinued operation (non-GAAP) | -High-teens | -Low-double digit | |
Impact of COVID-19 related testing, vaccines and therapeutics | +Low-double digit | +Low-double digit | |
Base business core sales decline from continuing operations reflecting Veralto as a discontinued operation (non- | -Mid-single digit | -Down slightly | |
GAAP) | |||
Three-Month Period
Ending December 31,
2023
Year Ending
December 31, 2023
Adjusted operating profit margin reflecting Veralto as a discontinued operation (non-GAAP) | ~28.0% | ~29.0% |
2
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit($ in millions)
Three-Month Period Ended | Nine-Month Period Ended | ||||||||||
September 29, 2023 | September 30, 2022 | September 29, 2023 | September 30, 2022 | ||||||||
Sales (GAAP) | |||||||||||
Biotechnology | $ | 1,664 | $ | 2,053 | $ | 5,413 | $ | 6,535 | |||
Life Sciences | 1,706 | 1,723 | 5,211 | 5,090 | |||||||
Diagnostics | 2,254 | 2,679 | 6,861 | 7,884 | |||||||
Environmental & Applied Solutions | 1,249 | 1,208 | 3,712 | 3,593 | |||||||
Total Company | $ | 6,873 | $ | 7,663 | $ | 21,197 | $ | 23,102 | |||
Operating Profit (GAAP) | |||||||||||
Biotechnology | $ | 417 | $ | 691 | $ | 1,493 | $ | 2,315 | |||
Life Sciences | 313 | 354 | 974 | 1,022 | |||||||
Diagnostics | 539 | 761 | 1,640 | 2,447 | |||||||
Environmental & Applied Solutions | 286 | 286 | 887 | 829 | |||||||
Other | (117) | (77) | (333) | (221) | |||||||
Total Company | $ | 1,438 | $ | 2,015 | $ | 4,661 | $ | 6,392 | |||
Amortization of Intangible Assets (GAAP) | |||||||||||
Biotechnology | $ | 214 | $ | 197 | $ | 649 | $ | 616 | |||
Life Sciences | 104 | 103 | 313 | 315 | |||||||
Diagnostics | 49 | 50 | 149 | 151 | |||||||
Environmental & Applied Solutions | 12 | 11 | 36 | 38 | |||||||
Total Company | $ | 379 | $ | 361 | $ | 1,147 | $ | 1,120 | |||
Other Operating Profit Adjustments 1 | |||||||||||
Biotechnology | $ | - | $ | - | $ | 42 | $ | 14 | |||
Life Sciences | - | - | - | 24 | |||||||
Diagnostics | - | - | - | 3 | |||||||
Environmental & Applied Solutions | 6 | - | 12 | 10 | |||||||
Other | 36 | - | 101 | 1 | |||||||
Total Company | $ | 42 | $ | - | $ | 155 | $ | 52 | |||
Adjusted Operating Profit (non-GAAP)2 | |||||||||||
Biotechnology | $ | 631 | $ | 888 | $ | 2,184 | $ | 2,945 | |||
Life Sciences | 417 | 457 | 1,287 | 1,361 | |||||||
Diagnostics | 588 | 811 | 1,789 | 2,601 | |||||||
Environmental & Applied Solutions | 304 | 297 | 935 | 877 | |||||||
Other | (81) | (77) | (232) | (220) | |||||||
Total Company | $ | 1,859 | $ | 2,376 | $ | 5,963 | $ | 7,564 | |||
- Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
- Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
3
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin($ in millions)
Three-Month Period Ended September 29, 2023 | |||||||||||||||||
Environmental & | |||||||||||||||||
Biotechnology | Life Sciences | Diagnostics | Applied | Other | Total Company | ||||||||||||
Solutions | |||||||||||||||||
Net Earnings (GAAP) | $ | 1,129 | |||||||||||||||
Interest, Net | (6) | ||||||||||||||||
Other Nonoperating (Income) Expense | 47 | ||||||||||||||||
Income Taxes | 268 | ||||||||||||||||
Operating Profit (GAAP) | $ | 417 | $ | 313 | $ | 539 | $ | 286 | $ | (117) | $ | 1,438 | |||||
Other Operating Profit Adjustments 1 | - | - | - | 6 | 36 | 42 | |||||||||||
Depreciation | 40 | 31 | 93 | 9 | 2 | 175 | |||||||||||
Amortization of Intangible Assets | 214 | 104 | 49 | 12 | - | 379 | |||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 671 | $ | 448 | $ | 681 | $ | 313 | $ | (79) | $ | 2,034 | |||||
Interest, Net | 6 | ||||||||||||||||
Other Nonoperating Income (Expense) | (47) | ||||||||||||||||
Income Taxes | (268) | ||||||||||||||||
Other Operating Profit Adjustments 1 | (42) | ||||||||||||||||
Depreciation | (175) | ||||||||||||||||
Amortization of Intangible Assets | (379) | ||||||||||||||||
Net Earnings (GAAP) | $ | 1,129 | |||||||||||||||
Sales (GAAP) | $ | 1,664 | $ | 1,706 | $ | 2,254 | $ | 1,249 | $ | 6,873 | |||||||
Net Earnings Margin (GAAP) | 16.4 % | ||||||||||||||||
Operating Profit Margin (GAAP) | 25.1 % | 18.3 % | 23.9 % | 22.9 % | 20.9 % | ||||||||||||
Adjusted EBITDA Margin (Non-GAAP)3 | 40.3 % | 26.3 % | 30.2 % | 25.1 % | 29.6 % | ||||||||||||
- Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
4
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin($ in millions)
Three-Month Period Ended September 30, 2022 | |||||||||||||||||
Environmental & | |||||||||||||||||
Biotechnology | Life Sciences | Diagnostics | Applied | Other | Total Company | ||||||||||||
Solutions | |||||||||||||||||
Net Earnings (GAAP) | $ | 1,572 | |||||||||||||||
Interest, Net | 33 | ||||||||||||||||
Other Nonoperating (Income) Expense | 51 | ||||||||||||||||
Income Taxes | 359 | ||||||||||||||||
Operating Profit (GAAP) | $ | 691 | $ | 354 | $ | 761 | $ | 286 | $ | (77) | $ | 2,015 | |||||
Other Operating Profit Adjustments 1 | - | - | - | - | - | - | |||||||||||
Depreciation | 40 | 29 | 98 | 10 | 2 | 179 | |||||||||||
Amortization of Intangible Assets | 197 | 103 | 50 | 11 | - | 361 | |||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 928 | $ | 486 | $ | 909 | $ | 307 | $ | (75) | $ | 2,555 | |||||
Interest, Net | (33) | ||||||||||||||||
Other Nonoperating Income (Expense) | (51) | ||||||||||||||||
Income Taxes | (359) | ||||||||||||||||
Other Operating Profit Adjustments 1 | - | ||||||||||||||||
Depreciation | (179) | ||||||||||||||||
Amortization of Intangible Assets | (361) | ||||||||||||||||
Net Earnings (GAAP) | $ | 1,572 | |||||||||||||||
Sales (GAAP) | $ | 2,053 | $ | 1,723 | $ | 2,679 | $ | 1,208 | $ | 7,663 | |||||||
Net Earnings Margin (GAAP) | 20.5 % | ||||||||||||||||
Operating Profit Margin (GAAP) | 33.7 % | 20.5 % | 28.4 % | 23.7 % | 26.3 % | ||||||||||||
Adjusted EBITDA Margin (Non-GAAP)3 | 45.2 % | 28.2 % | 33.9 % | 25.4 % | 33.3 % | ||||||||||||
- Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
5
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin($ in millions)
Nine-Month Period Ended September 29, 2023 | |||||||||||||||||
Environmental & | |||||||||||||||||
Biotechnology | Life Sciences | Diagnostics | Applied | Other | Total Company | ||||||||||||
Solutions | |||||||||||||||||
Net Earnings (GAAP) | $ | 3,685 | |||||||||||||||
Interest, Net | 22 | ||||||||||||||||
Other Nonoperating (Income) Expense | 52 | ||||||||||||||||
Income Taxes | 902 | ||||||||||||||||
Operating Profit (GAAP) | $ | 1,493 | $ | 974 | $ | 1,640 | $ | 887 | $ | (333) | $ | 4,661 | |||||
Other Operating Profit Adjustments 1 | 42 | - | - | 12 | 101 | 155 | |||||||||||
Depreciation | 119 | 92 | 282 | 29 | 4 | 526 | |||||||||||
Amortization of Intangible Assets | 649 | 313 | 149 | 36 | - | 1,147 | |||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 2,303 | $ | 1,379 | $ | 2,071 | $ | 964 | $ | (228) | $ | 6,489 | |||||
Interest, Net | (22) | ||||||||||||||||
Other Nonoperating Income (Expense) | (52) | ||||||||||||||||
Income Taxes | (902) | ||||||||||||||||
Other Operating Profit Adjustments 1 | (155) | ||||||||||||||||
Depreciation | (526) | ||||||||||||||||
Amortization of Intangible Assets | (1,147) | ||||||||||||||||
Net Earnings (GAAP) | $ | 3,685 | |||||||||||||||
Sales (GAAP) | $ | 5,413 | $ | 5,211 | $ | 6,861 | $ | 3,712 | $ | 21,197 | |||||||
Net Earnings Margin (GAAP) | 17.4 % | ||||||||||||||||
Operating Profit Margin (GAAP) | 27.6 % | 18.7 % | 23.9 % | 23.9 % | 22.0 % | ||||||||||||
Adjusted EBITDA Margin (Non-GAAP)3 | 42.5 % | 26.5 % | 30.2 % | 26.0 % | 30.6 % | ||||||||||||
- Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
6
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin($ in millions)
Nine-Month Period Ended September 30, 2022 | |||||||||||||||||
Environmental & | |||||||||||||||||
Biotechnology | Life Sciences | Diagnostics | Applied | Other | Total Company | ||||||||||||
Solutions | |||||||||||||||||
Net Earnings (GAAP) | $ | 4,977 | |||||||||||||||
Interest, Net | 135 | ||||||||||||||||
Other Nonoperating (Income) Expense | 158 | ||||||||||||||||
Income Taxes | 1,122 | ||||||||||||||||
Operating Profit (GAAP) | $ | 2,315 | $ | 1,022 | $ | 2,447 | $ | 829 | $ | (221) | $ | 6,392 | |||||
Other Operating Profit Adjustments 1 | 14 | 24 | 3 | 10 | 1 | 52 | |||||||||||
Depreciation | 127 | 84 | 290 | 31 | 5 | 537 | |||||||||||
Amortization of Intangible Assets | 616 | 315 | 151 | 38 | - | 1,120 | |||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 3,072 | $ | 1,445 | $ | 2,891 | $ | 908 | $ | (215) | $ | 8,101 | |||||
Interest, Net | (135) | ||||||||||||||||
Other Nonoperating Income (Expense) | (158) | ||||||||||||||||
Income Taxes | (1,122) | ||||||||||||||||
Other Operating Profit Adjustments 1 | (52) | ||||||||||||||||
Depreciation | (537) | ||||||||||||||||
Amortization of Intangible Assets | (1,120) | ||||||||||||||||
Net Earnings (GAAP) | $ | 4,977 | |||||||||||||||
Sales (GAAP) | $ | 6,535 | $ | 5,090 | $ | 7,884 | $ | 3,593 | $ | 23,102 | |||||||
Net Earnings Margin (GAAP) | 21.5 % | ||||||||||||||||
Operating Profit Margin (GAAP) | 35.4 % | 20.1 % | 31.0 % | 23.1 % | 27.7 % | ||||||||||||
Adjusted EBITDA Margin (Non-GAAP)3 | 47.0 % | 28.4 % | 36.7 % | 25.3 % | 35.1 % | ||||||||||||
- Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
7
DANAHER CORPORATION
Other Non-GAAPAdjusted P&L Measures($ in millions, except per share data)
Three-Month Period Ended September 29, 2023
Net earnings | Diluted net | |||||||||||||||||||||||
Earnings | for calculation | |||||||||||||||||||||||
Gross profit | Operating | Operating | of diluted | earnings per | ||||||||||||||||||||
Sales | Cost of sales | before | Income taxes | earnings per | common | |||||||||||||||||||
margin | profit | profit margin | income taxes | common share | share | |||||||||||||||||||
Reported (GAAP) | $ | 6,873 | $ | (2,873) | 58.2 % | $ | 1,438 | 20.9 % | $ | 1,397 | $ | (268) | $ | 1,129 | I | $ | 1.51 | |||||||
Amortization of acquisition-related | - | - | - | 379 | 5.5 | 379 | 379 | 0.51 | ||||||||||||||||
intangible assets A | ||||||||||||||||||||||||
Fair value net (gains) losses on | - | - | - | - | - | 48 | 48 | 0.06 | ||||||||||||||||
investments B | ||||||||||||||||||||||||
Separation costs C | - | - | - | 36 | 0.5 | 36 | 36 | 0.05 | ||||||||||||||||
Impairments and other charges D | - | - | - | 6 | 0.1 | 6 | 6 | 0.01 | ||||||||||||||||
Tax effect of the above adjustments F | (92) | (92) | (0.12) | |||||||||||||||||||||
Adjusted (Non-GAAP) | $ | 6,873 | $ | (2,873) | 58.2 % | $ | 1,859 | 27.0 % | $ | 1,866 | $ | (360) | $ | 1,506 | $ | 2.02 | ||||||||
Three-Month Period Ended September 29, 2023 | ||||||||||||||||||||||||
Selling, | Selling, | Research and | Nonoperating | Interest | ||||||||||||||||||||
general and | Research and | income | ||||||||||||||||||||||
general and | administrative | development | (expense), net | income | ||||||||||||||||||||
Sales | administrative | expenses as a | development | expenses as a | (excluding | (expense), | ||||||||||||||||||
expenses | % of sales | expenses | % of sales | interest) | net | |||||||||||||||||||
Reported (GAAP) | $ | 6,873 | $ | (2,145) | (31.2)% | $ | (417) | (6.1)% | $ | (47) | $ | 6 | ||||||||||||
Amortization of acquisition-related | - | 379 | 5.5 | - | - | - | - | |||||||||||||||||
intangible assets A | ||||||||||||||||||||||||
Fair value net (gains) losses on | - | - | - | - | - | 48 | - | |||||||||||||||||
investments B | ||||||||||||||||||||||||
Separation costs C | - | 36 | 0.5 | - | - | - | - | |||||||||||||||||
Impairments and other charges D | - | 6 | 0.1 | - | - | - | - | |||||||||||||||||
Adjusted (Non-GAAP) | $ | 6,873 | $ | (1,724) | (25.1)% | $ | (417) | (6.1)% | $ | 1 | $ | 6 | ||||||||||||
8
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Danaher Corporation published this content on 24 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2023 10:19:41 UTC.